{
    "nct_id": "NCT05823571",
    "official_title": "Phase 1a/1b Study of Itacitinib (INCB039110) for Cytokine Release Syndrome Prevention and Minimization of Immunosuppression Following Nonmyeloablative Related Partially HLA-mismatched Peripheral Blood Stem Cell Transplant (PBSCT) With High-dose Posttransplantation Cyclophosphamide in Older Patients (Age 60 Years)",
    "inclusion_criteria": "* Presence of a suitable related, HLA-haploidentical (partially mismatched) stem cell donor.\n* Eligible diagnoses:\n\n  1. Acute leukemias in complete remission with minimal residual disease\n  2. Myelodysplastic syndrome (MDS) with at least one poor-risk feature\n  3. Chronic myelomonocytic leukemia with at least one poor-risk feature\n  4. T-cell PLL in PR or better prior to transplantation.\n  5. Tyrosine kinase-refractory CML in first chronic phase, TKI-intolerant CML in first chronic phase, or CML in second or subsequent chronic phase.\n  6. Philadelphia chromosome negative myeloproliferative disease (including myelofibrosis)\n  7. Multiple myeloma or plasma cell leukemia with a PR or better to the last treatment regimen\n* Age ≥ 60 years.\n* Adequate end-organ function as measured by:\n\n  1. Left ventricular ejection fraction ≥ 35% or shortening fraction > 25%\n  2. Bilirubin ≤ 3.0 mg/dL (unless due to Gilbert's syndrome or hemolysis), and ALT and AST ≤ 5 x ULN\n  3. FEV1 and FVC ≥ 40% of predicted\n* ECOG performance status ≤ 2 or Karnofsky score ≥ 60\nHealthy volunteers allowed\nMust have minimum age of 60 Years",
    "exclusion_criteria": "* No active extramedullary leukemia or known active CNS involvement by malignancy.\n* Any previous autologous HSCT must have occurred at least 3 months prior to start of conditioning.\n* No previous allogeneic HSCT.\n* Not pregnant or breast-feeding\n* No uncontrolled infection.\n* No known HIV infection.\n* No active replicating HBV or HCV infection detected by PCR that requires treatment or at risk for HBV reactivation (positive HBsAg)",
    "miscellaneous_criteria": ""
}